NASDAQ:PBM Psyence Biomedical (PBM) Stock Price, News & Analysis $2.36 -2.67 (-53.08%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$3.98 +1.63 (+68.86%) As of 08/1/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Psyence Biomedical Stock (NASDAQ:PBM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Psyence Biomedical alerts:Sign Up Key Stats Today's Range$2.36▼$4.6850-Day Range$2.36▼$11.5052-Week Range$2.36▼$345.00Volume2.31 million shsAverage Volume1.94 million shsMarket Capitalization$1.35 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc. Read More Psyence Biomedical Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScorePBM MarketRank™: Psyence Biomedical scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Psyence Biomedical. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Book Value per Share RatioPsyence Biomedical has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.81% of the float of Psyence Biomedical has been sold short.Short Interest Ratio / Days to CoverPsyence Biomedical has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Psyence Biomedical has recently decreased by 37.98%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPsyence Biomedical does not currently pay a dividend.Dividend GrowthPsyence Biomedical does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.81% of the float of Psyence Biomedical has been sold short.Short Interest Ratio / Days to CoverPsyence Biomedical has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Psyence Biomedical has recently decreased by 37.98%, indicating that investor sentiment is improving significantly. News and Social Media2.4 / 5News Sentiment0.25 News SentimentPsyence Biomedical has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Psyence Biomedical this week, compared to 1 article on an average week.Search Interest4 people have searched for PBM on MarketBeat in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Psyence Biomedical insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.60% of the stock of Psyence Biomedical is held by insiders.Percentage Held by Institutions77.44% of the stock of Psyence Biomedical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Psyence Biomedical's insider trading history. Receive PBM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Psyence Biomedical and its competitors with MarketBeat's FREE daily newsletter. Email Address PBM Stock News HeadlinesPsyence Biomedical stock soars after partner achieves ibogaine breakthroughAugust 1 at 2:35 AM | za.investing.comPsyence Biomedical Shares Soar 70% Following Partner’s Ibogaine Extraction BreakthroughAugust 1 at 2:35 AM | msn.comJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% of his time focused on AI… but Nova is only part of the story. Behind the scenes, Amazon has been quietly investing in a breakthrough called “Helios” tech—a core enabler of the $40 trillion AI revolution. While Nova grabs headlines, this technology could be what truly transforms Amazon’s future. But one tiny startup—not Amazon—may offer the bigger upside.August 2 at 2:00 AM | Stansberry Research (Ad)Psyence BioMed’s Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine ProductionJuly 31 at 7:45 AM | financialpost.comFPsyence BioMed's Strategic Collaboration with PsyLabs Yields Breakthrough in High-Purity Ibogaine ProductionJuly 31 at 7:30 AM | globenewswire.comPSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common SharesJune 25, 2025 | globenewswire.comPsyence Biomedical regains Nasdaq compliance after reverse splitJune 18, 2025 | investing.comPSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common SharesJune 18, 2025 | globenewswire.comSee More Headlines PBM Stock Analysis - Frequently Asked Questions How have PBM shares performed this year? Psyence Biomedical's stock was trading at $16.8167 at the beginning of the year. Since then, PBM stock has decreased by 86.0% and is now trading at $2.36. How were Psyence Biomedical's earnings last quarter? Psyence Biomedical Ltd. (NASDAQ:PBM) posted its quarterly earnings results on Thursday, January, 23rd. The company reported $4.06 earnings per share for the quarter. When did Psyence Biomedical's stock split? Shares of Psyence Biomedical reverse split on the morning of Monday, May 5th 2025.A 100-797 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, May 4th 2025. An investor that had 100 shares of stock prior to the reverse split would have 13 shares after the split. Who are Psyence Biomedical's major shareholders? Psyence Biomedical's top institutional shareholders include Parallel Advisors LLC (48.25%). How do I buy shares of Psyence Biomedical? Shares of PBM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Psyence Biomedical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Psyence Biomedical investors own include BlackRock ESG Capital Allocation Term Trust (ECAT), Barings Global Short Duration High Yield Fund (BGH), BlackRock Innovation and Growth Term Trust (BIGZ), BlackRock Health Sciences Term Trust (BMEZ), Saba Capital Income & Opportunities Fund (BRW), BlackRock Science and Technology Term Trust (BSTZ) and Cameco (CCJ). Company Calendar Last Earnings1/23/2025Today8/02/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PBM Previous SymbolNASDAQ:PBM CIK1985062 Webwww.psyencebiomed.com Phone510-214-3750FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio11.04 Quick Ratio11.04 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.84 per share Price / Cash Flow2.81 Book Value$11.83 per share Price / Book0.20Miscellaneous Outstanding Shares570,000Free Float548,000Market Cap$1.35 million OptionableN/A Beta0.22 Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:PBM) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | SponsoredDon’t Touch Tesla Stock Without Reading This FirstJeff Brown says he wouldn’t touch Tesla stock right now—and the reason might shock you. A 40-year Wall Stre...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Psyence Biomedical Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Psyence Biomedical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.